{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"bdnf-p21","title":"BDNF-P21: P021, a four-amino-acid fragment that raises BDNF and works when eaten","body":"BDNF-P21 is sold as a peptide that raises BDNF, the growth factor nerve cells use to build and repair connections. That description is accurate and it is also the least interesting thing about the compound. The molecule is four amino acids long, it was cut out of a different growth factor entirely, it works when eaten rather than injected, and every result behind it comes from mice bred to have a genetic brain disease. The strongest of those results is real and specific: mice carrying the Down syndrome chromosome, treated from before birth, grew up without the memory failure they otherwise develop.\n\nThe site you are reading this on is funded by a business that sells this compound, which is exactly why the next sentence sits here at the top rather than at the bottom or nowhere. Nobody has given it to a person in a study: there is no human trial of it registered anywhere, under either of the names it goes by, on mouse data that goes back to 2014.\n\n## The name on the vial and the name in the papers are different\n\nSearch the literature for \"BDNF-P21\" and you will find almost nothing. The compound in every study below is called **P021**, and its written-out sequence is Ac-DGGL(A)G-NH2 — four amino acids with a chemical cap on each end.\n\nThe vendor name is a description of what the molecule does downstream, not its identity. P021 is not a piece of BDNF and it is not a BDNF copy. It came out of a different protein, and it raises BDNF indirectly. Anyone comparing prices or reading research needs the number, not the marketing name, or they will find nothing and assume nothing exists.\n\n## Four amino acids cut out of a different growth factor\n\nP021 was designed in Khalid Iqbal's laboratory at the New York State Institute for Basic Research in Developmental Disabilities on Staten Island, and the rights sit with a small company, Phanes Biotech. The starting material was ciliary neurotrophic factor, or CNTF — a growth factor that keeps nerve cells alive and pushes new ones to mature. The researchers identified the biologically active stretch of CNTF and built a four-amino-acid mimic of just that stretch.\n\nSo the chain is: a fragment modelled on CNTF's active region, which in a nerve cell drives more BDNF to be made, which then acts on nerve connections. Two steps, both documented, with the compound sitting at the top rather than in the middle.\n\n## Why a small piece instead of the whole protein\n\nThree separate attempts to treat brain disease by giving people whole growth-factor proteins failed, and they failed for the same three reasons every time. The proteins could not cross out of the blood into the brain. They were cleared from the body too fast to matter. And the doses needed to overcome both problems caused serious side effects.\n\nThat is the entire reason small mimics exist. A four-amino-acid molecule with caps on both ends is small enough to reach brain tissue, stable enough to survive the trip, and — the part that matters most in practice — it works mixed into food. Every long study below was run by putting P021 in the animals' diet, not by injecting them.\n\nFor a compound bought online, oral dosing is a genuine practical advantage over almost everything else in this category. It is also the reason the compound is sold as tablets rather than as a powder and a syringe.\n\n## What it does inside a nerve cell, step by step\n\nThe measurements in the mouse studies trace a specific chain, and each link was recorded separately rather than assumed:\n\n- BDNF levels rise in the brain tissue.\n- CREB, a switch that turns on the genes needed to build a synapse, gets phosphorylated — which is the chemical marker of it being switched on.\n- Proteins found on the sending side of the synapse stop disappearing, which in an untreated animal they do.\n- GSK3β activity falls. That enzyme is what puts too many phosphate groups onto tau, the structural protein that tangles in Alzheimer's disease.\n\nThat last item is why the researchers describe P021 as possibly disease-modifying rather than merely propping up function. Raising a growth factor could produce a temporary benefit that disappears when you stop. Turning down the enzyme that damages tau is a change to the process itself.\n\n## Twelve months of it in the diet of a mouse bred for Alzheimer's\n\nThe longest experiment: triple-transgenic Alzheimer's mice — animals carrying three human disease mutations — plus matched normal mice, fed P021 or a plain diet for twelve months, starting at nine to ten months of age, which in that model is well into established disease.\n\nWhat changed: abnormal tau phosphorylation and tau build-up fell significantly at the specific sites where Alzheimer's tangles form.\n\nWhat barely changed: the amyloid side. The effect on amyloid beta was limited to a fall in the soluble form, with the plaques essentially unmoved.\n\nBoth halves of that result matter. A compound that reduced tau damage across a year of treatment in an animal that was already sick is a real finding. A compound that leaves plaques alone is not the cure the category gets sold as.\n\n## Started at birth instead of at symptoms\n\nA second experiment ran the same Alzheimer's model the other way round: treatment in the diet from birth to day 120 of life, long before any symptoms appear. Mice treated that way did not develop the cognitive impairment the model produces, and the molecular markers of nerve-connection health were higher.\n\nThat is a prevention result in an animal with a known genetic fate, and it says something useful about the mechanism: the compound appears to act on how connections are built and maintained, rather than clearing away damage after the fact.\n\n## The Down syndrome experiment, which is the strongest result here\n\nThe most striking study used Ts65Dn mice, the standard model of Down syndrome, which show developmental delay in infancy and Alzheimer-type memory problems in adulthood. Treatment ran from before birth through early infancy — given to the mothers, then to the pups.\n\nThe reported outcome: the developmental delay was rescued, and the memory failures that appear in adult life did not appear. Alongside that, the loss of sending-side synaptic proteins was prevented, GSK3β activity fell, and BDNF and switched-on CREB were higher — measured twice, at three weeks old and again at about seven months.\n\nThe design is what gives that result its weight. The treatment stopped in infancy and the benefit was still measurable in middle age. That is not a drug propping up a symptom while it is in the body; it is an early intervention changing how a brain got built.\n\nIt is also, without qualification, mice.\n\n## The 2024 test in a mouse with a broken CDKL5 gene\n\nThe most recent work took P021 into another genetic disorder. Mutations in the CDKL5 gene cause a severe childhood epilepsy with motor and intellectual disability. Without that gene, nerve cells multiply, survive and mature poorly, and earlier work had shown that anything raising brain BDNF improves those animals.\n\nThe researchers tested P021 in cells and in the CDKL5 knockout mouse for exactly that reason: it was already documented as a BDNF-raiser in the Alzheimer's and Down syndrome models. That study is worth knowing about because of what it establishes about the compound's identity — three independent research groups now use it as a reliable way to raise brain BDNF in an animal. Its reputation inside the literature is as a research tool, and a well-behaved one.\n\n## What has never been done: no person, no injury, no trial\n\nA search of the clinical trials registry for P021 and for BDNF-P21 returns no study of this compound. Not a Phase 1, not a safety study, not a dose-finding study. It is not approved anywhere and it has not been submitted for approval.\n\nBeyond that, there is a second gap. Every study is a *genetic* disease of brain development or degeneration: Alzheimer's mutations, trisomy, a missing CDKL5 gene. There is no study of P021 in an injured nerve of any kind — not a crushed nerve, not a cut nerve, not a spinal cord injury, not a concussion, not nerve damage from chemotherapy or diabetes.\n\nWhere a compound has no safety record in people, unknown is not the same as safe. Nobody has measured what a year of raising BDNF does in a healthy adult brain, and BDNF signalling is not a system with only good outputs — the same pathway is involved in pain sensitisation.\n\n## The reasoning people use to get from these mice to a person, and where it breaks\n\nThe argument runs: damaged nerve tissue is short of BDNF, BDNF is what rebuilds nerve connections, P021 raises BDNF and can be swallowed, so P021 should help nerve tissue recover.\n\nEvery step in that chain is separately defensible. The chain has never been tested end to end, and there are two specific places it could fail.\n\nFirst, all the measurements are in brain tissue — hippocampus and cortex. A peripheral nerve is a different cell type with a different repair programme, and nothing in this literature measured one.\n\nSecond, the timing is inverted. Both of the strongest results came from treating *before* damage appeared. The one study that treated an animal already sick got a partial result: tau improved, plaques did not. Damage that is already years old is the second situation, not the first.\n\n## The finding that cuts against the whole idea: the growth factor it raises has a second job\n\nRaising BDNF is presented as unambiguously good. In nerve pain it is not, and the evidence for that is stronger and more specific than the evidence behind this compound.\n\nA 2024 review in *Neuroscience* by Peter Smith lays out the pathway. When a peripheral nerve is injured, its terminals in the spinal cord release signals that change the local immune cells — microglia — so they start carrying a particular receptor, P2X4. When nerve-released ATP hits that receptor, those microglia release BDNF. That BDNF then makes the excitatory neurons in the spinal cord's dorsal horn fire more easily and makes the inhibitory ones fire less easily, and it shifts the chloride balance inside neurons in a way that turns a normally calming signal into an exciting one. The result is amplified pain from a normal input.\n\nThe review's title is blunt about the whole line of work: BDNF is \"the culprit that cannot be apprehended\". And it reports something that ought to be in every conversation about this class of compound: in males, BDNF plays an obligatory role in the onset and maintenance of nerve pain, and in females it does not.\n\nSo the same molecule builds nerve connections in the brain and amplifies pain signalling in the spinal cord, and which of those you get depends on where it goes up, which cells release it, and — for pain specifically — sex. A compound whose entire mechanism is \"raise BDNF\" is running toward both effects at once, with no way to steer between them. Nobody has measured which one wins in a person, because nobody has given this compound to a person.\n\n## Where it sits next to the other BDNF-raisers sold beside it\n\nThree other compounds on this site work through the same growth factor, and the differences are worth having straight.\n\nSemax has been a hospital medicine in Russia for decades and has human data — small, mostly Russian, including a 110-patient stroke study where blood BDNF rose. Its rat measurement is a 1.4-fold rise in brain BDNF from a single dose into the nose. It also has one 2025 mouse study of a crushed spinal cord, which is the only nerve-injury result in this group.\n\nSelank keeps BDNF up in a different setting: in rats given alcohol long-term, seven days of it protected memory and kept BDNF up in the hippocampus and prefrontal cortex. Its human record is anxiety, not nerve repair.\n\nP021 has no human data at all, and the most rigorous animal designs of the three — treat before damage, measure decades-equivalent later, watch the marker stay changed.\n\nRead together, the group has an awkward shape. The compound with the best experimental design has never been near a person. The compound with human data has the weakest mechanism numbers. Nobody has run a head-to-head comparison of any two of them, in any species.\n\n## Oral, which is unusual and is the point\n\nAlmost everything sold in this category is a powder you mix with water and inject. P021 was designed to work in food, and every long-term study delivered it that way, which is why it is sold as tablets.\n\nPractically, that removes the two most common failure points in self-administered peptide use: mixing arithmetic and injection technique. It does not remove the more basic problem, which is that no human dose exists to copy. The mouse studies dosed by mixing a set concentration into diet across months. There is no published translation of that into a milligram figure for a person, and any number on a label is the seller's, not a researcher's.\n\n## What it would take to know\n\nA Phase 1 study in healthy adults would settle the safety question — what dose is tolerated, what happens to it in the body, whether measurable BDNF changes at all in a person. It has not been run, on a compound with mouse data going back to 2014.\n\nFor the nerve-injury question the study is different and harder: an animal model of actual nerve damage — a crushed sciatic nerve is the standard — with recovery measured against untreated controls. That study is straightforward, cheap by the standards of this field, and appears nowhere in the literature. Until somebody runs it, the case for using this compound on an injured nerve rests entirely on a mechanism, and the honest version of that sentence is that a mechanism is a hypothesis with a diagram attached.\n\nThere is a second study that would cost almost nothing and would settle the question that matters most on this page. Give the compound to male and female animals with an injured nerve, and measure pain behaviour rather than memory. If raising BDNF helps the nerve repair, pain should fall as function returns. If the spinal-cord pathway dominates, pain should rise, and rise in males more than females. Those two outcomes point in opposite directions and the experiment separates them in weeks. Twelve years after the first mouse paper, nobody has published it.\n\nUntil then, what can be said about BDNF-P21 is narrow and worth stating without decoration. It is a four-amino-acid piece modelled on CNTF that reliably raises BDNF in mouse brain tissue and can be eaten rather than injected. In three separate genetic diseases of the brain, given early, it changed how the animals' brains developed and the change outlasted the treatment. In an animal already sick it did about half of what it does when given early. Nobody has measured it in a person, nobody has measured it in an injured nerve, and the growth factor it raises has a documented second job of making nerve pain worse.\n\nSeven published studies are attached to this page, along with the registry search that returns nothing. Every claim above traces to one of them.\n","hero":"https://miscsubjects.com/img/gen/arcads-gpt-image-b8c2ba19-9ed3-462d-96d8-f27384b7b49c.png","images":[],"style":{},"tags":["peptide","bdnf","nerve-repair","p021","cntf"],"category":"research","model":"unattributed","ledger":{"href":"/api/articles/bdnf-p21/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"The compound sold as BDNF-P21 is called P021 in every published study, and its sequence is Ac-DGGL(A)G-NH2 - four amino acids with a cap on each end.","section":"what_it_is","tier":"structure","source_ids":["s1","s4"]},{"id":"c2","text":"P021 was cut from the biologically active region of ciliary neurotrophic factor, not from BDNF; it raises BDNF indirectly.","section":"mechanism","tier":"preclinical","source_ids":["s4"]},{"id":"c3","text":"Attempts to treat brain disease with whole neurotrophic proteins were halted because the proteins could not cross into the brain, were cleared too fast, and caused severe side effects. Small mimics exist to get past those three failures.","section":"mechanism","tier":"review","source_ids":["s5","s6"]},{"id":"c4","text":"In triple-transgenic Alzheimer's mice fed P021 for 12 months from 9-10 months of age, abnormal tau phosphorylation and accumulation fell significantly at the sites where tangles form, while the effect on amyloid was limited to a fall in the soluble form.","section":"what_is_known","tier":"preclinical","source_ids":["s1"]},{"id":"c5","text":"In Ts65Dn Down syndrome mice treated from before birth through early infancy, developmental delay was rescued and adult memory impairment did not appear; loss of pre-synaptic protein was prevented, GSK3-beta activity fell, and BDNF and phosphorylated CREB were higher at both 3 weeks and about 7 months.","section":"what_is_known","tier":"preclinical","source_ids":["s2"]},{"id":"c6","text":"In Alzheimer's-model mice fed P021 from birth to day 120, cognitive impairment did not develop and markers of nerve-connection health were higher.","section":"what_is_known","tier":"preclinical","source_ids":["s3"]},{"id":"c7","text":"Every long-term P021 study delivered the compound mixed into the animals' diet rather than by injection.","section":"what_is_known","tier":"preclinical","source_ids":["s1","s2","s3"]},{"id":"c8","text":"No human trial of P021 or BDNF-P21 is registered anywhere: no Phase 1, no safety study, no dose-finding study, on mouse data going back to 2014.","section":"what_is_unknown","tier":"human","source_ids":["s8"]},{"id":"c9","text":"Every P021 study is a genetic disease of brain development or degeneration. There is no study of it in an injured nerve, a compressed nerve root, a spinal cord injury, a tendon, a disc or a muscle.","section":"limitations","tier":"structure","source_ids":["s1","s2","s3","s4"]},{"id":"c10","text":"In males but not females, BDNF has an obligatory role in the onset and maintenance of nerve pain: microglia in the dorsal horn release it, and it makes excitatory spinal neurons fire more easily while making inhibitory ones fire less easily.","section":"limitations","tier":"review","source_ids":["s7"]},{"id":"c11","text":"No published head-to-head comparison exists between P021 and the other BDNF-raising compounds sold beside it.","section":"what_is_unknown","tier":"structure","source_ids":["s8"]}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25046994/","title":"Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease","quote":"3xTg-AD and wild type female mice were treated for 12 months with P021 (Ac-DGGL(A)G-NH2) or vehicle diet starting at 9-10 months of age. A significant reduction in abnormal hyperphosphorylation and accumulation of tau at known major AD neurofibrillary pathology associated sites was observed. The effect of P021 on Abeta pathology was limited to a significant decrease in soluble Abeta levels.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"genesis","hash":"c2e99937aecd5c8824cff3321a08006208768ebd9238764d887da8bf8c807007"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/28368015/","title":"Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome","quote":"Prenatal to early postnatal treatment with a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic, Peptide 021 (P021), rescued developmental delay in pups and AD-like hippocampus-dependent memory impairments in adult life in Ts65Dn mice. This treatment prevented pre-synaptic protein deficit, decreased glycogen synthase kinase-3beta (GSK3beta) activity, and increased levels of synaptic plasticity markers including BDNF and phosphorylated CREB, both in young (3-week-old) and adult (~7-month-old) mice.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"c2e99937aecd5c8824cff3321a08006208768ebd9238764d887da8bf8c807007","hash":"5519543e7e7f6016694006fc74e60cf0d5859992c673ade5368a9f010d47395a"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/34057082/","title":"Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction","quote":"3xTg-AD and genetic background-matched wild type female mice were treated from birth to postnatal day 120 with P021 in diet or with vehicle diet. P021 treatment during early development prevented cognitive impairment and increased markers of neuroplasticity.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"5519543e7e7f6016694006fc74e60cf0d5859992c673ade5368a9f010d47395a","hash":"e7f064da88d8c2a5b3e2e901446badc2b62c9d2026e29e1c7f696916f2eaf76c"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39592934/","title":"Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder","quote":"P021, a tetra-peptide derived from the biologically active region of the human ciliary neurotrophic factor (CNTF), was found to enhance neurogenesis and synaptic plasticity by promoting an increase in BDNF expression in preclinical models of brain disorders, such as Alzheimer's disease and Down syndrome.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"e7f064da88d8c2a5b3e2e901446badc2b62c9d2026e29e1c7f696916f2eaf76c","hash":"93807f47111e9f54b77ca274e57827243e5cf4ca751127076becf24b2e2aad2b"},{"id":"s5","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/36291618/","title":"Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound","quote":"Several attempts to use neurotrophic factors to treat AD were made, but these trials were halted due to their blood-brain barrier impermeability, short half-life, and severe side effects. We focus on a small neurotrophic and neurogenic peptide mimetic compound, P021, that was discovered in our laboratory and was found to overcome the difficulties faced in the administration of the whole neurotrophic factor proteins.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"93807f47111e9f54b77ca274e57827243e5cf4ca751127076becf24b2e2aad2b","hash":"75b9791098078ad4ba872f16f5e487ce976fa69804751fb57918fc15d481c5da"},{"id":"s6","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/27400746/","title":"Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease","quote":"The clinical therapeutic usage of recombinant neurotrophic factors is limited because of the insurmountable hurdles of unfavorable pharmacokinetic properties, poor blood-brain barrier permeability, and severe adverse effects.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"75b9791098078ad4ba872f16f5e487ce976fa69804751fb57918fc15d481c5da","hash":"46194a550c0ddadb11b1b6fa6376011fbebd56550e0878e4157d52ca314e194a"},{"id":"s7","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/38417539/","title":"BDNF in Neuropathic Pain; the Culprit that Cannot be Apprehended","quote":"In males but not in females, brain derived neurotrophic factor (BDNF) plays an obligatory role in the onset and maintenance of neuropathic pain. Afferent terminals of injured peripheral nerves release colony stimulating factor (CSF-1) and other mediators into the dorsal horn. These transform the phenotype of dorsal horn microglia such that they express P2X4 purinoceptors. Activation of these receptors by neuron-derived ATP promotes BDNF release. This microglial-derived BDNF increases synaptic activation of excitatory dorsal horn neurons and decreases that of inhibitory neurons. It also alters the neuronal chloride gradient.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"46194a550c0ddadb11b1b6fa6376011fbebd56550e0878e4157d52ca314e194a","hash":"f89172167dd542e1b673dd71d7bcdd89212777f7da76655e0a95289ed2f78601"},{"id":"s8","type":"statement","url":"https://clinicaltrials.gov/api/v2/studies?query.term=P021","title":"ClinicalTrials.gov registry search for P021 and BDNF-P21, run 4 August 2026","quote":"A registry query for P021 and for BDNF-P21 returns no study of this compound: no Phase 1, no safety study, no dose-finding study. The records the search returns are unrelated studies that match the string.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"f89172167dd542e1b673dd71d7bcdd89212777f7da76655e0a95289ed2f78601","hash":"a43a88ee4c1b48c57d43ffd635d02c9e0a8223205ee3fccf50c4d19638ba8775"}],"reviews":[],"extra":{},"has_traversal":false,"register":"essay","status":"published","revisions":5,"contributions":[],"provenance":[{"ts":"2026-08-04T21:38:25.119Z","model":"opus-5 (claude-code)","action":"write","why":"","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"eb1fc3eccdfa81d87529ef4c11160449a30c043d571037bb08bace4c87f4a5b2"}],"energy":{"passes":1,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"opus-5 (claude-code)":1},"head":"eb1fc3eccdfa81d87529ef4c11160449a30c043d571037bb08bace4c87f4a5b2"},"posted_at":"2026-08-04T21:38:25.119Z","created_at":"2026-08-04T21:38:25.119Z","updated_at":"2026-08-05T03:29:51.330Z","machine":{"shape":"article.machine/v1","slug":"bdnf-p21","kind":"article","read":{"human":"https://miscsubjects.com/a/bdnf-p21","json":"https://miscsubjects.com/api/articles/bdnf-p21","bundle":"https://miscsubjects.com/api/articles/bdnf-p21/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":11,"sources":8,"contributions":0,"revisions":5,"objections_url":"https://miscsubjects.com/api/articles/bdnf-p21/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=bdnf-p21","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"bdnf-p21\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"bdnf-p21\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/bdnf-p21/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"bdnf-p21\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/bdnf-p21 | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/bdnf-p21","json":"/api/articles/bdnf-p21","markdown":"/api/articles/bdnf-p21/bundle?format=markdown","skill":"/api/articles/bdnf-p21/skill","topology":"/api/articles/bdnf-p21/topology","versions":"/api/articles/bdnf-p21/revisions","invocations":"/api/articles/bdnf-p21/invocations"},"editorial_review":{"hero_brief":"a four-unit peptide fragment crossing the gut lining into the blood; the chain passing intact through the lining, with the ragged break showing it is a fragment","headline_subject":"bdnf p21","hero_subject":"a four-unit peptide fragment crossing the gut lining into the blood","visual_action":"the chain passing intact through the lining, with the ragged break showing it is a fragment","rationale":"what is distinctive about this compound is that it is four amino acids long, cut from something bigger, and survives being eaten. The previous hero was a photograph of a laboratory mouse — the research method, not the compound.","inspected":true,"inspection_note":"opened the file: painted lantern slide, four amber units with a visible break at one end, passing through the layered lining into a vessel with red cells, no animals or laboratory equipment anywhere in frame"},"editorial_audit":{"slug":"bdnf-p21","ok":true,"issues":[]},"body_hash":"b827640ad00bb3ee37e30d8db001bc399637c0cfc40b72c70efe6cdbe35232f0","object":{"object_type":"article-object","identity":{"id":"article:bdnf-p21","slug":"bdnf-p21","title":"BDNF-P21: P021, a four-amino-acid fragment that raises BDNF and works when eaten"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/bdnf-p21","role":"explain","audience":"human"},"skill":{"route":"/api/articles/bdnf-p21/skill","role":"direct behavior","audience":"model","content":"---\nname: bdnf-p21\ndescription: Apply the BDNF-P21: P021, a four-amino-acid fragment that raises BDNF and works when eaten article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# BDNF-P21: P021, a four-amino-acid fragment that raises BDNF and works when eaten\n\nThis Skill is the behavioral expression of [the canonical article](/a/bdnf-p21). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/bdnf-p21.\n- Read claims and relationships at /api/articles/bdnf-p21/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nBDNF-P21 is sold as a peptide that raises BDNF, the growth factor nerve cells use to build and repair connections. That description is accurate and it is also the least interesting thing about the compound. The molecule is four amino acids \n\n## Representations\n\n- Human: /a/bdnf-p21\n- JSON: /api/articles/bdnf-p21\n- Relationships: /api/articles/bdnf-p21/topology\n- History: /api/articles/bdnf-p21/revisions\n"},"json":{"route":"/api/articles/bdnf-p21","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/bdnf-p21/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","bdnf","nerve-repair","p021","cntf","bdnf","p21"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/bdnf-p21/invocations?status=success","failure_events":"/api/articles/bdnf-p21/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"bdnf-p21","title":"BDNF-P21: P021, a four-amino-acid fragment that raises BDNF and works when eaten","body":"BDNF-P21 is sold as a peptide that raises BDNF, the growth factor nerve cells use to build and repair connections. That description is accurate and it is also the least interesting thing about the compound. The molecule is four amino acids long, it was cut out of a different growth factor entirely, it works when eaten rather than injected, and every result behind it comes from mice bred to have a genetic brain disease. The strongest of those results is real and specific: mice carrying the Down syndrome chromosome, treated from before birth, grew up without the memory failure they otherwise develop.\n\nThe site you are reading this on is funded by a business that sells this compound, which is exactly why the next sentence sits here at the top rather than at the bottom or nowhere. Nobody has given it to a person in a study: there is no human trial of it registered anywhere, under either of the names it goes by, on mouse data that goes back to 2014.\n\n## The name on the vial and the name in the papers are different\n\nSearch the literature for \"BDNF-P21\" and you will find almost nothing. The compound in every study below is called **P021**, and its written-out sequence is Ac-DGGL(A)G-NH2 — four amino acids with a chemical cap on each end.\n\nThe vendor name is a description of what the molecule does downstream, not its identity. P021 is not a piece of BDNF and it is not a BDNF copy. It came out of a different protein, and it raises BDNF indirectly. Anyone comparing prices or reading research needs the number, not the marketing name, or they will find nothing and assume nothing exists.\n\n## Four amino acids cut out of a different growth factor\n\nP021 was designed in Khalid Iqbal's laboratory at the New York State Institute for Basic Research in Developmental Disabilities on Staten Island, and the rights sit with a small company, Phanes Biotech. The starting material was ciliary neurotrophic factor, or CNTF — a growth factor that keeps nerve cells alive and pushes new ones to mature. The researchers identified the biologically active stretch of CNTF and built a four-amino-acid mimic of just that stretch.\n\nSo the chain is: a fragment modelled on CNTF's active region, which in a nerve cell drives more BDNF to be made, which then acts on nerve connections. Two steps, both documented, with the compound sitting at the top rather than in the middle.\n\n## Why a small piece instead of the whole protein\n\nThree separate attempts to treat brain disease by giving people whole growth-factor proteins failed, and they failed for the same three reasons every time. The proteins could not cross out of the blood into the brain. They were cleared from the body too fast to matter. And the doses needed to overcome both problems caused serious side effects.\n\nThat is the entire reason small mimics exist. A four-amino-acid molecule with caps on both ends is small enough to reach brain tissue, stable enough to survive the trip, and — the part that matters most in practice — it works mixed into food. Every long study below was run by putting P021 in the animals' diet, not by injecting them.\n\nFor a compound bought online, oral dosing is a genuine practical advantage over almost everything else in this category. It is also the reason the compound is sold as tablets rather than as a powder and a syringe.\n\n## What it does inside a nerve cell, step by step\n\nThe measurements in the mouse studies trace a specific chain, and each link was recorded separately rather than assumed:\n\n- BDNF levels rise in the brain tissue.\n- CREB, a switch that turns on the genes needed to build a synapse, gets phosphorylated — which is the chemical marker of it being switched on.\n- Proteins found on the sending side of the synapse stop disappearing, which in an untreated animal they do.\n- GSK3β activity falls. That enzyme is what puts too many phosphate groups onto tau, the structural protein that tangles in Alzheimer's disease.\n\nThat last item is why the researchers describe P021 as possibly disease-modifying rather than merely propping up function. Raising a growth factor could produce a temporary benefit that disappears when you stop. Turning down the enzyme that damages tau is a change to the process itself.\n\n## Twelve months of it in the diet of a mouse bred for Alzheimer's\n\nThe longest experiment: triple-transgenic Alzheimer's mice — animals carrying three human disease mutations — plus matched normal mice, fed P021 or a plain diet for twelve months, starting at nine to ten months of age, which in that model is well into established disease.\n\nWhat changed: abnormal tau phosphorylation and tau build-up fell significantly at the specific sites where Alzheimer's tangles form.\n\nWhat barely changed: the amyloid side. The effect on amyloid beta was limited to a fall in the soluble form, with the plaques essentially unmoved.\n\nBoth halves of that result matter. A compound that reduced tau damage across a year of treatment in an animal that was already sick is a real finding. A compound that leaves plaques alone is not the cure the category gets sold as.\n\n## Started at birth instead of at symptoms\n\nA second experiment ran the same Alzheimer's model the other way round: treatment in the diet from birth to day 120 of life, long before any symptoms appear. Mice treated that way did not develop the cognitive impairment the model produces, and the molecular markers of nerve-connection health were higher.\n\nThat is a prevention result in an animal with a known genetic fate, and it says something useful about the mechanism: the compound appears to act on how connections are built and maintained, rather than clearing away damage after the fact.\n\n## The Down syndrome experiment, which is the strongest result here\n\nThe most striking study used Ts65Dn mice, the standard model of Down syndrome, which show developmental delay in infancy and Alzheimer-type memory problems in adulthood. Treatment ran from before birth through early infancy — given to the mothers, then to the pups.\n\nThe reported outcome: the developmental delay was rescued, and the memory failures that appear in adult life did not appear. Alongside that, the loss of sending-side synaptic proteins was prevented, GSK3β activity fell, and BDNF and switched-on CREB were higher — measured twice, at three weeks old and again at about seven months.\n\nThe design is what gives that result its weight. The treatment stopped in infancy and the benefit was still measurable in middle age. That is not a drug propping up a symptom while it is in the body; it is an early intervention changing how a brain got built.\n\nIt is also, without qualification, mice.\n\n## The 2024 test in a mouse with a broken CDKL5 gene\n\nThe most recent work took P021 into another genetic disorder. Mutations in the CDKL5 gene cause a severe childhood epilepsy with motor and intellectual disability. Without that gene, nerve cells multiply, survive and mature poorly, and earlier work had shown that anything raising brain BDNF improves those animals.\n\nThe researchers tested P021 in cells and in the CDKL5 knockout mouse for exactly that reason: it was already documented as a BDNF-raiser in the Alzheimer's and Down syndrome models. That study is worth knowing about because of what it establishes about the compound's identity — three independent research groups now use it as a reliable way to raise brain BDNF in an animal. Its reputation inside the literature is as a research tool, and a well-behaved one.\n\n## What has never been done: no person, no injury, no trial\n\nA search of the clinical trials registry for P021 and for BDNF-P21 returns no study of this compound. Not a Phase 1, not a safety study, not a dose-finding study. It is not approved anywhere and it has not been submitted for approval.\n\nBeyond that, there is a second gap. Every study is a *genetic* disease of brain development or degeneration: Alzheimer's mutations, trisomy, a missing CDKL5 gene. There is no study of P021 in an injured nerve of any kind — not a crushed nerve, not a cut nerve, not a spinal cord injury, not a concussion, not nerve damage from chemotherapy or diabetes.\n\nWhere a compound has no safety record in people, unknown is not the same as safe. Nobody has measured what a year of raising BDNF does in a healthy adult brain, and BDNF signalling is not a system with only good outputs — the same pathway is involved in pain sensitisation.\n\n## The reasoning people use to get from these mice to a person, and where it breaks\n\nThe argument runs: damaged nerve tissue is short of BDNF, BDNF is what rebuilds nerve connections, P021 raises BDNF and can be swallowed, so P021 should help nerve tissue recover.\n\nEvery step in that chain is separately defensible. The chain has never been tested end to end, and there are two specific places it could fail.\n\nFirst, all the measurements are in brain tissue — hippocampus and cortex. A peripheral nerve is a different cell type with a different repair programme, and nothing in this literature measured one.\n\nSecond, the timing is inverted. Both of the strongest results came from treating *before* damage appeared. The one study that treated an animal already sick got a partial result: tau improved, plaques did not. Damage that is already years old is the second situation, not the first.\n\n## The finding that cuts against the whole idea: the growth factor it raises has a second job\n\nRaising BDNF is presented as unambiguously good. In nerve pain it is not, and the evidence for that is stronger and more specific than the evidence behind this compound.\n\nA 2024 review in *Neuroscience* by Peter Smith lays out the pathway. When a peripheral nerve is injured, its terminals in the spinal cord release signals that change the local immune cells — microglia — so they start carrying a particular receptor, P2X4. When nerve-released ATP hits that receptor, those microglia release BDNF. That BDNF then makes the excitatory neurons in the spinal cord's dorsal horn fire more easily and makes the inhibitory ones fire less easily, and it shifts the chloride balance inside neurons in a way that turns a normally calming signal into an exciting one. The result is amplified pain from a normal input.\n\nThe review's title is blunt about the whole line of work: BDNF is \"the culprit that cannot be apprehended\". And it reports something that ought to be in every conversation about this class of compound: in males, BDNF plays an obligatory role in the onset and maintenance of nerve pain, and in females it does not.\n\nSo the same molecule builds nerve connections in the brain and amplifies pain signalling in the spinal cord, and which of those you get depends on where it goes up, which cells release it, and — for pain specifically — sex. A compound whose entire mechanism is \"raise BDNF\" is running toward both effects at once, with no way to steer between them. Nobody has measured which one wins in a person, because nobody has given this compound to a person.\n\n## Where it sits next to the other BDNF-raisers sold beside it\n\nThree other compounds on this site work through the same growth factor, and the differences are worth having straight.\n\nSemax has been a hospital medicine in Russia for decades and has human data — small, mostly Russian, including a 110-patient stroke study where blood BDNF rose. Its rat measurement is a 1.4-fold rise in brain BDNF from a single dose into the nose. It also has one 2025 mouse study of a crushed spinal cord, which is the only nerve-injury result in this group.\n\nSelank keeps BDNF up in a different setting: in rats given alcohol long-term, seven days of it protected memory and kept BDNF up in the hippocampus and prefrontal cortex. Its human record is anxiety, not nerve repair.\n\nP021 has no human data at all, and the most rigorous animal designs of the three — treat before damage, measure decades-equivalent later, watch the marker stay changed.\n\nRead together, the group has an awkward shape. The compound with the best experimental design has never been near a person. The compound with human data has the weakest mechanism numbers. Nobody has run a head-to-head comparison of any two of them, in any species.\n\n## Oral, which is unusual and is the point\n\nAlmost everything sold in this category is a powder you mix with water and inject. P021 was designed to work in food, and every long-term study delivered it that way, which is why it is sold as tablets.\n\nPractically, that removes the two most common failure points in self-administered peptide use: mixing arithmetic and injection technique. It does not remove the more basic problem, which is that no human dose exists to copy. The mouse studies dosed by mixing a set concentration into diet across months. There is no published translation of that into a milligram figure for a person, and any number on a label is the seller's, not a researcher's.\n\n## What it would take to know\n\nA Phase 1 study in healthy adults would settle the safety question — what dose is tolerated, what happens to it in the body, whether measurable BDNF changes at all in a person. It has not been run, on a compound with mouse data going back to 2014.\n\nFor the nerve-injury question the study is different and harder: an animal model of actual nerve damage — a crushed sciatic nerve is the standard — with recovery measured against untreated controls. That study is straightforward, cheap by the standards of this field, and appears nowhere in the literature. Until somebody runs it, the case for using this compound on an injured nerve rests entirely on a mechanism, and the honest version of that sentence is that a mechanism is a hypothesis with a diagram attached.\n\nThere is a second study that would cost almost nothing and would settle the question that matters most on this page. Give the compound to male and female animals with an injured nerve, and measure pain behaviour rather than memory. If raising BDNF helps the nerve repair, pain should fall as function returns. If the spinal-cord pathway dominates, pain should rise, and rise in males more than females. Those two outcomes point in opposite directions and the experiment separates them in weeks. Twelve years after the first mouse paper, nobody has published it.\n\nUntil then, what can be said about BDNF-P21 is narrow and worth stating without decoration. It is a four-amino-acid piece modelled on CNTF that reliably raises BDNF in mouse brain tissue and can be eaten rather than injected. In three separate genetic diseases of the brain, given early, it changed how the animals' brains developed and the change outlasted the treatment. In an animal already sick it did about half of what it does when given early. Nobody has measured it in a person, nobody has measured it in an injured nerve, and the growth factor it raises has a documented second job of making nerve pain worse.\n\nSeven published studies are attached to this page, along with the registry search that returns nothing. Every claim above traces to one of them.\n","hero":"https://miscsubjects.com/img/gen/arcads-gpt-image-b8c2ba19-9ed3-462d-96d8-f27384b7b49c.png","images":[],"style":{},"tags":["peptide","bdnf","nerve-repair","p021","cntf"],"category":"research","model":"unattributed","ledger":{"href":"/api/articles/bdnf-p21/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"The compound sold as BDNF-P21 is called P021 in every published study, and its sequence is Ac-DGGL(A)G-NH2 - four amino acids with a cap on each end.","section":"what_it_is","tier":"structure","source_ids":["s1","s4"]},{"id":"c2","text":"P021 was cut from the biologically active region of ciliary neurotrophic factor, not from BDNF; it raises BDNF indirectly.","section":"mechanism","tier":"preclinical","source_ids":["s4"]},{"id":"c3","text":"Attempts to treat brain disease with whole neurotrophic proteins were halted because the proteins could not cross into the brain, were cleared too fast, and caused severe side effects. Small mimics exist to get past those three failures.","section":"mechanism","tier":"review","source_ids":["s5","s6"]},{"id":"c4","text":"In triple-transgenic Alzheimer's mice fed P021 for 12 months from 9-10 months of age, abnormal tau phosphorylation and accumulation fell significantly at the sites where tangles form, while the effect on amyloid was limited to a fall in the soluble form.","section":"what_is_known","tier":"preclinical","source_ids":["s1"]},{"id":"c5","text":"In Ts65Dn Down syndrome mice treated from before birth through early infancy, developmental delay was rescued and adult memory impairment did not appear; loss of pre-synaptic protein was prevented, GSK3-beta activity fell, and BDNF and phosphorylated CREB were higher at both 3 weeks and about 7 months.","section":"what_is_known","tier":"preclinical","source_ids":["s2"]},{"id":"c6","text":"In Alzheimer's-model mice fed P021 from birth to day 120, cognitive impairment did not develop and markers of nerve-connection health were higher.","section":"what_is_known","tier":"preclinical","source_ids":["s3"]},{"id":"c7","text":"Every long-term P021 study delivered the compound mixed into the animals' diet rather than by injection.","section":"what_is_known","tier":"preclinical","source_ids":["s1","s2","s3"]},{"id":"c8","text":"No human trial of P021 or BDNF-P21 is registered anywhere: no Phase 1, no safety study, no dose-finding study, on mouse data going back to 2014.","section":"what_is_unknown","tier":"human","source_ids":["s8"]},{"id":"c9","text":"Every P021 study is a genetic disease of brain development or degeneration. There is no study of it in an injured nerve, a compressed nerve root, a spinal cord injury, a tendon, a disc or a muscle.","section":"limitations","tier":"structure","source_ids":["s1","s2","s3","s4"]},{"id":"c10","text":"In males but not females, BDNF has an obligatory role in the onset and maintenance of nerve pain: microglia in the dorsal horn release it, and it makes excitatory spinal neurons fire more easily while making inhibitory ones fire less easily.","section":"limitations","tier":"review","source_ids":["s7"]},{"id":"c11","text":"No published head-to-head comparison exists between P021 and the other BDNF-raising compounds sold beside it.","section":"what_is_unknown","tier":"structure","source_ids":["s8"]}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25046994/","title":"Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease","quote":"3xTg-AD and wild type female mice were treated for 12 months with P021 (Ac-DGGL(A)G-NH2) or vehicle diet starting at 9-10 months of age. A significant reduction in abnormal hyperphosphorylation and accumulation of tau at known major AD neurofibrillary pathology associated sites was observed. The effect of P021 on Abeta pathology was limited to a significant decrease in soluble Abeta levels.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"genesis","hash":"c2e99937aecd5c8824cff3321a08006208768ebd9238764d887da8bf8c807007"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/28368015/","title":"Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome","quote":"Prenatal to early postnatal treatment with a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic, Peptide 021 (P021), rescued developmental delay in pups and AD-like hippocampus-dependent memory impairments in adult life in Ts65Dn mice. This treatment prevented pre-synaptic protein deficit, decreased glycogen synthase kinase-3beta (GSK3beta) activity, and increased levels of synaptic plasticity markers including BDNF and phosphorylated CREB, both in young (3-week-old) and adult (~7-month-old) mice.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"c2e99937aecd5c8824cff3321a08006208768ebd9238764d887da8bf8c807007","hash":"5519543e7e7f6016694006fc74e60cf0d5859992c673ade5368a9f010d47395a"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/34057082/","title":"Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction","quote":"3xTg-AD and genetic background-matched wild type female mice were treated from birth to postnatal day 120 with P021 in diet or with vehicle diet. P021 treatment during early development prevented cognitive impairment and increased markers of neuroplasticity.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"5519543e7e7f6016694006fc74e60cf0d5859992c673ade5368a9f010d47395a","hash":"e7f064da88d8c2a5b3e2e901446badc2b62c9d2026e29e1c7f696916f2eaf76c"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39592934/","title":"Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder","quote":"P021, a tetra-peptide derived from the biologically active region of the human ciliary neurotrophic factor (CNTF), was found to enhance neurogenesis and synaptic plasticity by promoting an increase in BDNF expression in preclinical models of brain disorders, such as Alzheimer's disease and Down syndrome.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"e7f064da88d8c2a5b3e2e901446badc2b62c9d2026e29e1c7f696916f2eaf76c","hash":"93807f47111e9f54b77ca274e57827243e5cf4ca751127076becf24b2e2aad2b"},{"id":"s5","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/36291618/","title":"Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound","quote":"Several attempts to use neurotrophic factors to treat AD were made, but these trials were halted due to their blood-brain barrier impermeability, short half-life, and severe side effects. We focus on a small neurotrophic and neurogenic peptide mimetic compound, P021, that was discovered in our laboratory and was found to overcome the difficulties faced in the administration of the whole neurotrophic factor proteins.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"93807f47111e9f54b77ca274e57827243e5cf4ca751127076becf24b2e2aad2b","hash":"75b9791098078ad4ba872f16f5e487ce976fa69804751fb57918fc15d481c5da"},{"id":"s6","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/27400746/","title":"Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease","quote":"The clinical therapeutic usage of recombinant neurotrophic factors is limited because of the insurmountable hurdles of unfavorable pharmacokinetic properties, poor blood-brain barrier permeability, and severe adverse effects.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"75b9791098078ad4ba872f16f5e487ce976fa69804751fb57918fc15d481c5da","hash":"46194a550c0ddadb11b1b6fa6376011fbebd56550e0878e4157d52ca314e194a"},{"id":"s7","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/38417539/","title":"BDNF in Neuropathic Pain; the Culprit that Cannot be Apprehended","quote":"In males but not in females, brain derived neurotrophic factor (BDNF) plays an obligatory role in the onset and maintenance of neuropathic pain. Afferent terminals of injured peripheral nerves release colony stimulating factor (CSF-1) and other mediators into the dorsal horn. These transform the phenotype of dorsal horn microglia such that they express P2X4 purinoceptors. Activation of these receptors by neuron-derived ATP promotes BDNF release. This microglial-derived BDNF increases synaptic activation of excitatory dorsal horn neurons and decreases that of inhibitory neurons. It also alters the neuronal chloride gradient.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"46194a550c0ddadb11b1b6fa6376011fbebd56550e0878e4157d52ca314e194a","hash":"f89172167dd542e1b673dd71d7bcdd89212777f7da76655e0a95289ed2f78601"},{"id":"s8","type":"statement","url":"https://clinicaltrials.gov/api/v2/studies?query.term=P021","title":"ClinicalTrials.gov registry search for P021 and BDNF-P21, run 4 August 2026","quote":"A registry query for P021 and for BDNF-P21 returns no study of this compound: no Phase 1, no safety study, no dose-finding study. The records the search returns are unrelated studies that match the string.","accessed_at":"2026-08-04T21:38:25.119Z","prev":"f89172167dd542e1b673dd71d7bcdd89212777f7da76655e0a95289ed2f78601","hash":"a43a88ee4c1b48c57d43ffd635d02c9e0a8223205ee3fccf50c4d19638ba8775"}],"reviews":[],"extra":{},"has_traversal":false,"register":"essay","status":"published","revisions":5,"contributions":[],"provenance":[{"ts":"2026-08-04T21:38:25.119Z","model":"opus-5 (claude-code)","action":"write","why":"","prompt":"","input":"","response":"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"eb1fc3eccdfa81d87529ef4c11160449a30c043d571037bb08bace4c87f4a5b2"}],"energy":{"passes":1,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"opus-5 (claude-code)":1},"head":"eb1fc3eccdfa81d87529ef4c11160449a30c043d571037bb08bace4c87f4a5b2"},"posted_at":"2026-08-04T21:38:25.119Z","created_at":"2026-08-04T21:38:25.119Z","updated_at":"2026-08-05T03:29:51.330Z","machine":{"shape":"article.machine/v1","slug":"bdnf-p21","kind":"article","read":{"human":"https://miscsubjects.com/a/bdnf-p21","json":"https://miscsubjects.com/api/articles/bdnf-p21","bundle":"https://miscsubjects.com/api/articles/bdnf-p21/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":11,"sources":8,"contributions":0,"revisions":5,"objections_url":"https://miscsubjects.com/api/articles/bdnf-p21/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=bdnf-p21","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"bdnf-p21\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"bdnf-p21\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/bdnf-p21/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"bdnf-p21\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/bdnf-p21 | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/bdnf-p21","json":"/api/articles/bdnf-p21","markdown":"/api/articles/bdnf-p21/bundle?format=markdown","skill":"/api/articles/bdnf-p21/skill","topology":"/api/articles/bdnf-p21/topology","versions":"/api/articles/bdnf-p21/revisions","invocations":"/api/articles/bdnf-p21/invocations"},"editorial_review":{"hero_brief":"a four-unit peptide fragment crossing the gut lining into the blood; the chain passing intact through the lining, with the ragged break showing it is a fragment","headline_subject":"bdnf p21","hero_subject":"a four-unit peptide fragment crossing the gut lining into the blood","visual_action":"the chain passing intact through the lining, with the ragged break showing it is a fragment","rationale":"what is distinctive about this compound is that it is four amino acids long, cut from something bigger, and survives being eaten. The previous hero was a photograph of a laboratory mouse — the research method, not the compound.","inspected":true,"inspection_note":"opened the file: painted lantern slide, four amber units with a visible break at one end, passing through the layered lining into a vessel with red cells, no animals or laboratory equipment anywhere in frame"},"editorial_audit":{"slug":"bdnf-p21","ok":true,"issues":[]},"body_hash":"b827640ad00bb3ee37e30d8db001bc399637c0cfc40b72c70efe6cdbe35232f0"}}}